<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00752726</url>
  </required_header>
  <id_info>
    <org_study_id>W3600586</org_study_id>
    <nct_id>NCT00752726</nct_id>
  </id_info>
  <brief_title>Effect of Orlistat in Body Composition</brief_title>
  <official_title>The Effects of Weight Reduction With Orlistat vs. Placebo on Changes in Body Composition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a 24 week weight loss program with orlistat 60
      mg will produce greater changes in body composition compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Large amounts of VAT (adipose tissue surrounding the viscera of the organs), is known to be
      associated with increased risk of heart disease and diabetes. Orlistat (tetrahydrolipstatin
      or THL) inhibits gastrointestinal lipase and reduces the absorption of dietary fat. The
      purpose of this study is to to determine if a 24 week weight loss program with orlistat 60 mg
      would produce greater changes in adipose tissue depots (specifically VAT) compared to
      placebo. This study will use the Echo MRI technology across multiple sites to measure total
      fat mass. EchoMRI is a non invasive method ideally suited for studies which track changes in
      human body composition over time, with measuring times of less than 3 minutes and no
      radiation exposure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 24 in Abdominal VAT Mass</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>VAT was measured by the computed tomography (CT) scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Abdominal VAT Mass</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Abdominal VAT mass from baseline to week 12 was measured by CT scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Body Weight</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>Participants were weighed at least twice until two consecutive measurements were within 0.5 kg of each other and the average of the two measurements was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Total Fat Mass</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>Change in total fat mass was calculated from an average of three measurements at each visit from Echo Magnetic Resonance Imaging (EchoMRI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Percentage Body Fat</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>Body fat was assessed through Bioelectrical Impedance Analysis (BIA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Waist Circumference</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>Waist circumference was measured against the skin, without interference from clothing, at the level midway between the lateral lower rib margin and the iliac crest in standing position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Percentage Liver Fat</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>For Liver fat, Intrahepatic lipids (IHL) were measured by Magnetic Resonance Spectroscopy (MRS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Liver Fat</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>The liver fat was measured by CT scan in Hounsfield Units (HU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Total Calories Expended for Physical Activity</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>Measurement of physical activity from Paffenbarger questionnaire. The number of caloried expended was representation of activity level: Higher calorie counts indicate higher activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Quality of Life (QoL) Scores.</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>QoL scores were measured using an Impact of Weight Quality of Life (IWQoL) Questionnaire, which scored the responses at a scale of 1 to 5(1, never true, to 5, always true): QoL scales for physical function, self-esteem, sexual life, public distress, and work were evaluated, and summarized in a total score. A higher value indicated a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Selectivity Index at Week 24</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>The selectivity index (SI) was used as a measure of orlistat's ability to target abdominal VAT loss compared to total adipose tissue lost. SI was calculated using the following equation: Mean % change in VAT divided by Mean % change in total fat mass.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Orlistat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Orlistat 60 milligram (mg) capsules to be consumed orally with each meal 3 times per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match Orlistat 60 mg capsules to be consumed orally with each meal 3 times per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orlistat</intervention_name>
    <description>Weight loss treatment</description>
    <arm_group_label>Orlistat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-60 years inclusive

          -  Body Mass Index (BMI): BMI in the range of 25.0-34.9 kg/m^2

          -  Waist circumference:

        Females: &gt; 35 inches Males: &gt; 40 inches

          -  Diet:

               1. Normal eating habits, consuming 3 meals a day (breakfast, lunch and dinner)

               2. Willing to follow a hypocaloric diet during the study to achieve weight loss

               3. Willing to take a daily multivitamin for the duration of the study.

          -  General Health:Good general health with (in the opinion of the investigator) no
             clinically significant and relevant abnormalities of medical history or physical
             examination

        Exclusion Criteria:

          -  Pregnant and/ or Breast-feeding women

          -  Diet/Exercise:Currently on a special diet or who cannot fulfill the dietary
             requirements of the study.

          -  Smoking History:a) Smoking cessation within the past 6 months b) Current Smokers

          -  Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study
             materials and study foods (or closely related compounds) or any of their stated
             ingredients.

          -  Medication:

             a) Currently taking medication for weight loss or appetite control. b) Previous
             Xenical® (orlistat) or alli® use within 3 months of screening date c) Currently taking
             medication or supplements that influence intestinal transit time and other stool
             formation parameters or influences cramping (e.g., Anticholinergics (such as atropine)
             or cholinergics (such as physostigmine), phenothiazines, tricyclic antidepressants,
             opioid analgesics (including loperamide), calcium channel antagonists, clonidine,
             cisapride, octreotide. Also, any laxative or antidiarrheal product). d) Currently
             taking or withdrawn during the past 6 months any drugs with significant impact on body
             weight (e.g. serotoninergically acting drugs, antidepressants, central adrenergically
             acting drugs, drugs inhibiting digestion and absorption, appetite suppressants,
             metformin) e) Currently taking Cyclosporine, Warfarin or Amiodarone HCL

          -  Disease/Surgery:

             a) History of gastrointestinal disease (e.g., irritable bowel syndrome, diarrhea,
             inflamed bowel, steatorrhea/fat malabsorption, hemorrhoids, incontinence,
             pancreatitis). b) History of psychological disorder, including eating disorders such
             as anorexia nervosa and bulimia c) History of neurological disorder (e.g. seizures,
             parkinson's disease, Alzheimer's disease) d) History of hypo/hyperthyroidism unless
             euthyroid and controlled on a stable dose of medication for at least 6 months. e)
             History of surgery for weight loss f) Uncontrolled hypertension g) Heart Disease h)
             Diabetes Mellitus (Type 1 and 2) (Fasting Blood Glucose &gt;126 mg/dL)

          -  Participant has a known history of panic attacks and/or claustrophobia or other
             conditions precluding safe EchoMRI, CT or other scanning modalities according to local
             guidelines, (e.g., pacemaker, hearing aid, metallic body piercing and/or other metal
             implants) or in the opinion of the Investigator the participant exceeds size
             limitations for the instruments.

          -  Participant has had a weight loss or gain of greater than or equal to 3 kg in the 3
             months prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Clinical Research Unit</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Academy</name>
      <address>
        <city>Goteborg</city>
        <state>West Gothland</state>
        <zip>405 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Smith SR, Stenlof KS, Greenway FL, McHutchison J, Schwartz SM, Dev VB, Berk ES, Kapikian R. Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial. Obesity (Silver Spring). 2011 Sep;19(9):1796-803. doi: 10.1038/oby.2011.143. Epub 2011 Jun 30.</citation>
    <PMID>21720429</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2008</study_first_submitted>
  <study_first_submitted_qc>September 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2008</study_first_posted>
  <results_first_submitted>July 21, 2010</results_first_submitted>
  <results_first_submitted_qc>January 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 7, 2013</results_first_posted>
  <last_update_submitted>February 28, 2013</last_update_submitted>
  <last_update_submitted_qc>February 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>overweight, orlistat, body composition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This multicentric clinical study was conducted in 2 countries; 2 centres in United States of America (USA) and 1 centre in Sweden.</recruitment_details>
      <pre_assignment_details>Out of 267 screened participants, 131 were randomized, while 136 participants were considered as screen failures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Orlistat 60 Milligram (mg)</title>
          <description>Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo to match orlistat 60 mg capsules taken orally with meals 3 times per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="63">2 participants were never dosed with the study medication.</participants>
                <participants group_id="P2" count="64">2 participants were never dosed with the study medication.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intention to Treat (ITT) Population</title>
              <participants_list>
                <participants group_id="P1" count="62">ITT population had atleast 1 post treatment efficacy measurement.</participants>
                <participants group_id="P2" count="61">ITT population had atleast 1 post treatment efficacy measurement.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Orlistat 60 mg</title>
          <description>Orlistat 60 mg capsules taken orally with meals 3 times per day. Intent-to-treat (ITT) population was considered for baseline measures.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo to match Orlistat 60 mg capsules taken orally with meals 3 times per day. ITT population was considered for baseline measures.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="123"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.92" spread="9.031"/>
                    <measurement group_id="B2" value="43.84" spread="11.682"/>
                    <measurement group_id="B3" value="43.37" spread="10.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>Kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.10" spread="10.705"/>
                    <measurement group_id="B2" value="87.79" spread="9.354"/>
                    <measurement group_id="B3" value="87.95" spread="10.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Centimeter (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.30" spread="8.275"/>
                    <measurement group_id="B2" value="168.08" spread="8.117"/>
                    <measurement group_id="B3" value="168.19" spread="8.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>Kilogram per meter square (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.03" spread="2.259"/>
                    <measurement group_id="B2" value="31.04" spread="2.064"/>
                    <measurement group_id="B3" value="31.03" spread="2.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100.10" spread="7.967"/>
                    <measurement group_id="B2" value="100.60" spread="6.892"/>
                    <measurement group_id="B3" value="100.35" spread="7.427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visceral Abdominal Tissue (VAT) Mass</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.75" spread="1.870"/>
                    <measurement group_id="B2" value="3.92" spread="1.806"/>
                    <measurement group_id="B3" value="3.83" spread="1.832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 24 in Abdominal VAT Mass</title>
        <description>VAT was measured by the computed tomography (CT) scan.</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Orlistat 60 mg</title>
            <description>Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Abdominal VAT Mass</title>
          <description>VAT was measured by the computed tomography (CT) scan.</description>
          <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.630" spread="0.6887"/>
                    <measurement group_id="O2" value="-0.403" spread="0.7249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis considered no difference in the change from baseline to week 24 between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0244</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Mean change was adjusted for treatment, baseline VAT and center effect using an ANCOVA model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>0.263</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1150</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.035</ci_lower_limit>
            <ci_upper_limit>0.491</ci_upper_limit>
            <estimate_desc>Adjusted mean difference between Placebo group and Orlistat group was determined. For this primary analysis, only one statistical test was performed and therefore, no multiple comparison adjustment was done.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Abdominal VAT Mass</title>
        <description>Abdominal VAT mass from baseline to week 12 was measured by CT scan.</description>
        <time_frame>Baseline to week 12</time_frame>
        <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Orlistat 60 mg</title>
            <description>Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Abdominal VAT Mass</title>
          <description>Abdominal VAT mass from baseline to week 12 was measured by CT scan.</description>
          <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.496" spread="0.4943"/>
                    <measurement group_id="O2" value="-0.351" spread="0.5904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis considered no difference in the change from baseline to week 12 between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0415</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Mean change was adjusted for the treatment, baseline VAT and center effects using an ANCOVA model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>0.172</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0834</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.007</ci_lower_limit>
            <ci_upper_limit>0.337</ci_upper_limit>
            <estimate_desc>Adjusted mean difference between Placebo group and Orlistat group was determined.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Body Weight</title>
        <description>Participants were weighed at least twice until two consecutive measurements were within 0.5 kg of each other and the average of the two measurements was recorded.</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Orlistat 60 mg</title>
            <description>Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Body Weight</title>
          <description>Participants were weighed at least twice until two consecutive measurements were within 0.5 kg of each other and the average of the two measurements was recorded.</description>
          <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.96" spread="4.743"/>
                    <measurement group_id="O2" value="-3.91" spread="5.375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis considered no difference in the change from baseline to week 24 between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Mean change was adjusted for the treatment, baseline weight and center effects, using an ANCOVA model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>1.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.881</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>3.74</ci_upper_limit>
            <estimate_desc>Adjusted mean difference between Placebo group and Orlistat group was determined.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Total Fat Mass</title>
        <description>Change in total fat mass was calculated from an average of three measurements at each visit from Echo Magnetic Resonance Imaging (EchoMRI).</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Orlistat 60 mg</title>
            <description>Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Total Fat Mass</title>
          <description>Change in total fat mass was calculated from an average of three measurements at each visit from Echo Magnetic Resonance Imaging (EchoMRI).</description>
          <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.69" spread="3.691"/>
                    <measurement group_id="O2" value="-3.16" spread="4.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis considered no difference in the change from baseline to week 24 between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0242</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Mean change was adjusted for the treatment, baseline total fat mass and center effects using an ANCOVA model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>1.642</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7174</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.219</ci_lower_limit>
            <ci_upper_limit>3.065</ci_upper_limit>
            <estimate_desc>Adjusted mean difference between placebo group and Orlistat group was determined.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Percentage Body Fat</title>
        <description>Body fat was assessed through Bioelectrical Impedance Analysis (BIA).</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Orlistat 60 mg</title>
            <description>Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Percentage Body Fat</title>
          <description>Body fat was assessed through Bioelectrical Impedance Analysis (BIA).</description>
          <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment.</population>
          <units>Percentage (%) body fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.70" spread="3.434"/>
                    <measurement group_id="O2" value="-0.38" spread="4.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis considered no difference in the change from baseline to week 24 between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Mean was adjusted for the treatment, baseline total fat mass and center effects using an ANCOVA model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>1.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.704</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>2.87</ci_upper_limit>
            <estimate_desc>Adjusted mean difference between placebo group and Orlistat group was evaluated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Waist Circumference</title>
        <description>Waist circumference was measured against the skin, without interference from clothing, at the level midway between the lateral lower rib margin and the iliac crest in standing position.</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Orlistat 60 mg</title>
            <description>Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Waist Circumference</title>
          <description>Waist circumference was measured against the skin, without interference from clothing, at the level midway between the lateral lower rib margin and the iliac crest in standing position.</description>
          <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.65" spread="0.692"/>
                    <measurement group_id="O2" value="-4.95" spread="0.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis considered no difference in the change from baseline to week 24 between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.085</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Mean change was adjusted for the treatment, baseline waist circumference and center effects, using an ANCOVA model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>1.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.974</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>3.63</ci_upper_limit>
            <estimate_desc>Adjusted mean difference between Placebo group and Orlistat group was determined.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Percentage Liver Fat</title>
        <description>For Liver fat, Intrahepatic lipids (IHL) were measured by Magnetic Resonance Spectroscopy (MRS).</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>ITT subset (participants who had this post-baseline efficacy assessment) from one study site was analysed for this parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Orlistat 60 mg</title>
            <description>Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Percentage Liver Fat</title>
          <description>For Liver fat, Intrahepatic lipids (IHL) were measured by Magnetic Resonance Spectroscopy (MRS).</description>
          <population>ITT subset (participants who had this post-baseline efficacy assessment) from one study site was analysed for this parameter.</population>
          <units>Percentage (%) IHL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0008" spread="0.00609"/>
                    <measurement group_id="O2" value="-0.0112" spread="0.03642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Liver Fat</title>
        <description>The liver fat was measured by CT scan in Hounsfield Units (HU).</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Orlistat 60 mg</title>
            <description>Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Liver Fat</title>
          <description>The liver fat was measured by CT scan in Hounsfield Units (HU).</description>
          <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment.</population>
          <units>Hounsfield Units (HU)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.169"/>
                    <measurement group_id="O2" value="0.02" spread="0.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis considered no difference in the change from baseline to week 24 between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3235</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Mean change was adjusted for the treatment, baseline liver fat and center effects, using an ANCOVA model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.023</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0232</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.069</ci_lower_limit>
            <ci_upper_limit>0.023</ci_upper_limit>
            <estimate_desc>Adjusted mean difference between placebo group and Orlistat group was evaluated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Total Calories Expended for Physical Activity</title>
        <description>Measurement of physical activity from Paffenbarger questionnaire. The number of caloried expended was representation of activity level: Higher calorie counts indicate higher activity</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Orlistat 60 mg</title>
            <description>Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Total Calories Expended for Physical Activity</title>
          <description>Measurement of physical activity from Paffenbarger questionnaire. The number of caloried expended was representation of activity level: Higher calorie counts indicate higher activity</description>
          <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment.</population>
          <units>Kilocalorie (kcal)/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-498" spread="6627"/>
                    <measurement group_id="O2" value="517" spread="4873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis considered no difference in the change from baseline to week 24 between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Mean change was adjusted for the treatment, baseline total calories expended and center effects using an ANCOVA model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>783.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>726.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-657.3</ci_lower_limit>
            <ci_upper_limit>2224.9</ci_upper_limit>
            <estimate_desc>Adjusted mean difference between placebo group and Orlistat group was evaluated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Quality of Life (QoL) Scores.</title>
        <description>QoL scores were measured using an Impact of Weight Quality of Life (IWQoL) Questionnaire, which scored the responses at a scale of 1 to 5(1, never true, to 5, always true): QoL scales for physical function, self-esteem, sexual life, public distress, and work were evaluated, and summarized in a total score. A higher value indicated a better quality of life.</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>This analysis was carried out for the observed ITT population, i.e. ITT subjects who had this post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Orlistat 60 mg</title>
            <description>Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Quality of Life (QoL) Scores.</title>
          <description>QoL scores were measured using an Impact of Weight Quality of Life (IWQoL) Questionnaire, which scored the responses at a scale of 1 to 5(1, never true, to 5, always true): QoL scales for physical function, self-esteem, sexual life, public distress, and work were evaluated, and summarized in a total score. A higher value indicated a better quality of life.</description>
          <population>This analysis was carried out for the observed ITT population, i.e. ITT subjects who had this post-baseline efficacy assessment.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="8.009"/>
                    <measurement group_id="O2" value="8.78" spread="10.429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis considered no difference in the change from baseline to week 24 between the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2847</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Mean difference was adjusted for the treatment, baseline value and center effects using an ANCOVA model.</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>1.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.542</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.40</ci_lower_limit>
            <ci_upper_limit>4.72</ci_upper_limit>
            <estimate_desc>Adjusted mean difference was calculated as placebo minus orlistat.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Selectivity Index at Week 24</title>
        <description>The selectivity index (SI) was used as a measure of orlistat’s ability to target abdominal VAT loss compared to total adipose tissue lost. SI was calculated using the following equation: Mean % change in VAT divided by Mean % change in total fat mass.</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment, only in Orlistat 60 mg group. This analysis was not carried out for placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Orlistat 60 mg</title>
            <description>Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Selectivity Index at Week 24</title>
          <description>The selectivity index (SI) was used as a measure of orlistat’s ability to target abdominal VAT loss compared to total adipose tissue lost. SI was calculated using the following equation: Mean % change in VAT divided by Mean % change in total fat mass.</description>
          <population>This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment, only in Orlistat 60 mg group. This analysis was not carried out for placebo group.</population>
          <units>Ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events encountered or spontaneously reported by the participant following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Orlistat 60 mg</title>
          <description>Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo to match Orlistat 60 mg capsules taken orally with meals 3 times per day</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Biliary tract disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fatty/oily stool</sub_title>
                <counts group_id="E1" events="36" subjects_affected="22" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Soft stools</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="63"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="63"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Liquid stools</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Increased defecation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Fecal urgency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Flatus with discharge</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Oily spotting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="63"/>
                <counts group_id="E2" events="33" subjects_affected="22" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

